FOLFOX6方案对患者结肠癌细胞生物特性影响的研究

Effect of neoadjuvant chemotherapy on biological characteristics of colon cancer cells in patients

目的探究新辅助放化疗对患者结肠癌细胞生物特性的影响.方法选取2012-01/2015-12期间嘉兴市第二医院收治的68例结肠癌为研究对象,将患者采用随机数表法分为对照组和观察组,各34例.给予对照组患者结肠癌根治手术和常规术后放化疗,观察组患者在此基础上进行术前新辅助放化疗.对比2组患者癌胚抗原(carcino-embryonic antigen,CEA)、血管内皮生长因子受体2(vascular endothelial growth factor receptor 2,VEGFR2)、增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)的阳性表达率,2组患者治疗后20 mo的复发率和生存率.结果观察组与对照组患者的CEA阳性表达率分别为58.83%和85.30%,VEGFR2阳性表达率分别为44.10%和67.63%,PCNA阳性表达率分别为47.04%和73.54%,差异具有统计学意义(P<0.05).术后20 mo观察组患者的复发率和生存率分别为14.70%和70.58%,对照组患者的复发率和生存率分别为38.23%和47.05%,差异具有统计学意义(P<0.05).结论术前新辅助放化疗能够降低结肠癌患者癌组织中CEA、VEGFR2和PCNA的表达,抑制结肠癌肿瘤细胞的增殖、转移,促进结肠癌肿瘤细胞凋亡,降低复发率,提高生存率.

AIM To explore the effect of neoadjuvant chemotherapy on the biological characteristics of colon cancer cells in patients. METHODS Sixty-eight patients with colon cancer treated at our hospital from January 2012 to December 2015 were randomly divided into either a control group or an observation group, with 34 cases in each group. The patients in the control group underwent radical operation and postoperative radiotherapy and chemotherapy, and the observation group received neoadjuvant radiotherapy and chemotherapy before operation. The recurrence rate and survival rate at 30 mo after treatment were compared between the two groups of patients. The positive rates of carcino-embryonic antigen （CEA）, vascular endothelial growth factor receptor 2 （VEGFR2） and proliferating cell nuclear antigen （PCNA） were also compared. RESULTS The positive rates of CEA, VEGFR2, and PCNA were significantly lower in the observation group than in the control group （58.83% vs 85.30%, 44.10% vs 67.63%, 47.04% vs 73.54%, P 〈 0.05）. At 20 mo after surgery, the recurrence rate and survival rate were significantly lower in the observation group than in the control group （14.70% vs 38.23%, 70.58% vs 47.05%, P 〈 0.05）. CONCLUSIOH Neoadjuvant chemotherapy can reduce the expression of CEA, VEGFR2 and PCNA in cancer tissue, inhibit tumor cell proliferation and metastasis, promote tumor cell apoptosis, reduce recurrence, and improve survival in patients with colon cancer.